首页> 外文OA文献 >EFSA ND A Panel ( EFSA Panel on Dietetic Products, Nutrition and Allergies), 2013. Scientific Opinion on the substantiation of a health claim related to eicosapentanoic acid (EPA) and “ reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the d evelopment of attention difficulties in children with ADHD - like symptoms ” pursuant to Article 14 of Regulation (EC) No 1924/2006
【2h】

EFSA ND A Panel ( EFSA Panel on Dietetic Products, Nutrition and Allergies), 2013. Scientific Opinion on the substantiation of a health claim related to eicosapentanoic acid (EPA) and “ reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the d evelopment of attention difficulties in children with ADHD - like symptoms ” pursuant to Article 14 of Regulation (EC) No 1924/2006

机译:EFsa ND a小组(EFsa饮食产品,营养和过敏专家组),2013年。关于证实与二十碳五烯酸(Epa)相关的健康声明的科学意见,并“降低血液中的aa / Epa比率。高aa / Epa水平是根据第(EC)1924/2006号条例第14条,在患有注意力缺陷症的儿童中发生注意力困难的风险因素。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Following an application from Minami Nutrition Health BVBA, submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to eicosapentaenoic acid (EPA) and “reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the development of attention difficulties in children with attention deficit hyperactivity disorder (ADHD)-like symptoms”. The food constituent, EPA, which is the subject of the health claim, is sufficiently characterised. The claimed effect proposed by the applicant is “reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the development of attention difficulties in children with ADHD-like symptoms. These children are also characterised by less hyperactivity and/or coexisting oppositional behaviour”. Upon a request by EFSA for clarification, the applicant indicated that the disease was ADHD, which is classified as such in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), that the risk factor for the disease was an elevated AA/EPA ratio in blood, and that the target population for the claim was children with diagnosis of ADHD. The Panel considers that the evidence provided does not establish that reducing the AA/EPA ratio reduces the risk of ADHD in children, and considers that the target population is a diseased population (i.e. children with ADHD). The Panel concludes that the claimed effect relates to the treatment of a disease, and that therefore the health claim does not comply with the criteria laid down in Regulation (EC) No 1924/2006.© European Food Safety Authority, 2013
机译:在Minami Nutrition Health BVBA根据比利时法规(EC)第1924/2006条第14条通过比利时主管当局提交的申请后,要求EFSA营养产品,营养和过敏专门委员会(NDA)对与二十碳五烯酸(EPA)有关的健康声明的科学依据,并“降低了血液中的AA / EPA比。高AA / EPA水平是患有注意力缺陷多动障碍(ADHD)样症状的儿童注意力困难发展的危险因素。”作为健康声明主题的食品成分EPA具有足够的特征。申请人提出的要求保护的作用是“降低血液中的AA / EPA比率。高AA / EPA水平是ADHD样症状儿童注意力障碍发展的危险因素。这些儿童的特征还在于少动症和/或同时存在对立行为”。经欧洲食品安全局(EFSA)要求澄清,申请人指出该疾病为ADHD,根据《精神疾病诊断和统计手册》(DSM-IV)分类为ADHD,该疾病的危险因素是AA升高/ EPA血液中的比率,该声明的目标人群是患有ADHD的儿童。专家小组认为,所提供的证据并未证明降低AA / EPA比率会降低儿童多动症的风险,并认为目标人群是患病人群(即多动症儿童)。专家组得出结论认为,所声称的效果与疾病的治疗有关,因此,健康声明不符合法规(EC)1924/2006的规定。©欧洲食品安全局,2013年

著录项

  • 作者

    Tetens Inge;

  • 作者单位
  • 年度 2013
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号